FSH-FSHR信号通路在2型糖尿病性骨质疏松症中的研究进展

doi:10.3969/j.issn.1003-9198.2026.04.018

摘要/Abstract

摘要： 2型糖尿病性骨质疏松症(T2DOP)是一种在糖代谢紊乱背景下发生的慢性骨代谢疾病,以 “高骨密度、低骨质量” 为特征,患者骨折风险显著升高。近年来,卵泡刺激素(FSH)及其受体(FSHR)信号通路在T2DOP发病机制中的作用日益受到关注。FSH除调控性腺功能外,还可通过分布于胰腺、肝脏、脂肪和骨组织中的FSHR,参与糖代谢与骨代谢的双向调节。本文系统综述了FSH-FSHR信号通路在T2DOP中的作用机制,并探讨靶向该通路的治疗策略,为T2DOP的防治提供新思路。

关键词: 卵泡刺激素, 卵泡刺激素受体, 信号通路, 2型糖尿病性骨质疏松症, 糖代谢, 骨代谢

Abstract: Type 2 diabetic osteoporosis (T2DOP) is a chronic bone metabolic disorder occurring in the context of disordered glucose metabolism, characterized by a unique“high bone density, low bone quality”phenotype and significantly increase fracture risk. Recently, the follicle-stimulating hormone (FSH) and its receptor (FSHR) signaling pathway has attracted increasing attention for its role in the pathogenesis of T2DOP. In addition to regulating gonadal function, FSH can also participate in the bidirectional regulation of glucose metabolism and bone metabolism through FSHR distributed in the pancreas, liver, adipose tissue, and bone tissue. This article systematically reviews the mechanism of action of the FSH-FSHR signaling pathway in T2DOP and explores therapeutic strategies targeting this pathway, providing novel insights for the prevention and treatment of T2DOP.

Key words: follicle-stimulating hormone, follicle-stimulating hormone receptor, signaling pathway, type 2 diabetic osteoporosis, glucose metabolism, bone metabolism

中图分类号:

韩星艳, 高飞. FSH-FSHR信号通路在2型糖尿病性骨质疏松症中的研究进展[J]. 实用老年医学, 2026, 40(4): 422-426.

HAN Xingyan, GAO Fei. Research progress of FSH-FSHR signaling pathway in type 2 diabetic osteoporosis[J]. Practical Geriatrics, 2026, 40(4): 422-426.

参考文献

[1] American Diabetes Association.Classification and diagnosis of diabetes:standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1):S13-S33.
[2] DUNCAN B B, MAGLIANO D J, BOYKO E J. IDF Diabetes Atlas 11th edition 2025:global prevalence and projections for 2050[J]. Nephrol Dial Transplant, 2025, 41(1):7-9.
[3] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14):1671-1691.
[4] FERRARI S L, ABRAHAMSEN B, NAPOLI N, et al. Diagnosis and management of bone fragility in diabetes:an emerging challenge[J]. Osteoporos Int, 2018, 29(12):2585-2596.
[5] WU B, FU Z, WANG X, et al. A narrative review of diabetic bone disease:characteristics, pathogenesis, and treatment[J]. Front Endocrinol:Lausanne, 2022, 13:1052592.
[6] RANDOLPH J F, ZHENG H, SOWERS M R, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition:effect of age at the final menstrualperiod[J]. J Clin Endocrinol Metab, 2011, 96(3):746-754.
[7] ZUMOFF B, STRAIN G W, KREAM J, et al. Age variation of the 24-hour mean plasma concentrations of androgens, estrogens, and gonadotropins in normal adult men[J]. J Clin Endocrinol Metab, 1982, 54(3):534-538.
[8] SUN L, PENG Y, SHARROW A C, et al. FSH directly regulates bone mass[J]. Cell, 2006, 125(2):247-260.
[9] 赵彩霞, 刘鹏. 卵泡刺激素新的代谢调控功能及对衰老的影响[J]. 生理学报, 2021, 73(5):755-760.
[10] CHENG Y, ZHU H, REN J, et al. Follicle-stimulating hormone orchestrates glucose-stimulated insulin secretion of pancreatic islets[J]. Nat Commun, 2023, 14(1):6991.
[11] HALDAR S, AGRAWAL H, SAHA S, et al. Overview of follicle stimulating hormone and its receptors in reproduction and in stem cells and cancer stem cells[J]. Int J Biol Sci, 2022, 18(2):675-692.
[12] BHARTIYA D, PATEL H. An overview of FSH-FSHR biology and explaining the existing conundrums[J]. J Ovarian Res, 2021, 14(1):144.
[13] KORKMAZ F, GIMENEZ-ROIG J, SULTANA F, et al. Targeting FSH for osteoporosis, obesity, and Alzheimer’s disease[J]. Trends Mol Med, 2025, 31(11):1021-1031.
[14] ULLOA-AGUIRRE A, REITER E, CRÉPIEUX P. FSH receptor signaling:complexity of interactions and signal diversity[J]. Endocrinology, 2018, 159(8):3020-3035.
[15] LANDOMIEL F, DE PASCALI F, RAYNAUD P, et al. Biased signaling and allosteric modulation at the FSHR[J]. Front Endocrinol:Lausanne, 2019, 10:148.
[16] CHU C, XU B, HUANG W. A study on expression of FSH and its effects on the secretion of insulin and glucagon in rat pancreas[J]. Tissue Cell, 2010, 42(6):370-375.
[17] QI X, GUO Y, SONG Y, et al. Follicle-stimulating hormone enhances hepatic gluconeogenesis by GRK2-mediated AMPK hyperphosphorylation at Ser485 in mice[J]. Diabetologia, 2018, 61(5):1180-1192.
[18] MATTICK L J, BEA J W, SINGH L, et al. Serum follicle-stimulating hormone and 5-year change in adiposity in healthy postmenopausal women[J]. J Clin Endocrinol Metab, 2022, 107(8):e3455-e3462.
[19] LIU P, JI Y, YUEN T, et al. Blocking FSH induces thermogenic adipose tissue and reduces body fat[J]. Nature, 2017, 546(7656):107-112.
[20] 伍西羽, 廖二元, 肖业. 卵泡刺激素抗体预防骨质疏松和肥胖[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018, 11(5):496-502.
[21] LIMMER A, WIRTZ D C. Osteoimmunology:influence of the immune system on bone regeneration and consumption[J]. Z Orthop Unfall, 2017, 155(3):273-280.
[22] CANNON J G, CORTEZ-COOPER M, MEADERS E, et al. Follicle-stimulating hormone, interleukin-1, and bone density in adult women[J]. Am J Physiol Regul Integr Comp Physiol, 2010, 298(3):R790-R798.
[23] KITAURA H, MARAHLEH A, OHORI F, et al. Osteocyte-related cytokines regulate osteoclast formation and bone resorption[J]. Int J Mol Sci, 2020, 21(14):5169.
[24] IQBAL J, SUN L, KUMAR T R, et al. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation[J]. Proc Natl Acad Sci U S A, 2006, 103(40):14925-14930.
[25] MARAHLEH A, KITAURA H, OHORI F, et al. TNF-α directly enhances osteocyte RANKL expression and promotes osteoclast formation[J]. Front Immunol, 2019, 10:2925.
[26] CHEN J, LIAO Y, SHENG Y, et al. FSH exacerbates bone loss by promoting osteoclast energy metabolism through the CREB-MDH2-NAD(+) axis[J]. Metabolism, 2025, 165:156147.
[27] TOURKOVA I L, WITT M R, LI L, et al. Follicle stimulating hormone receptor in mesenchymal stem cells integrates effects of glycoprotein reproductive hormones[J]. Ann N Y Acad Sci, 2015, 1335(1):100-109.
[28] LIANG B, BURLEY G, LIN S, et al. Osteoporosis pathogenesis and treatment:existing and emerging avenues[J]. Cell Mol Biol Lett, 2022, 27(1):72.
[29] NING Q, LI M, LIAO Z, et al. LncRNA MRF targeting FSHR inhibits the osteogenic differentiation of BMSCs and bone defect repair through the regulation of the cAMP-PKA-CREB signaling pathway[J]. Stem Cell Res Ther, 2025, 16(1):200.
[30] JI Y, LIU P, YUEN T, et al. Epitope-specific monoclonal antibodies to FSHβ increase bone mass[J]. Proc Natl Acad Sci U S A, 2018, 115(9):2192-2197.
[31] GERA S, SANT D, HAIDER S, et al. First-in-class humanized FSH blocking antibody targets bone and fat[J]. Proc Natl Acad Sci U S A, 2020, 117(46):28971-28979.
[32] GERA S, KUO T C, GUMEROVA A A, et al. FSH-blocking therapeutic for osteoporosis[J]. eLife, 2022, 11:e78022.
[33] YAO H, ZHANG A, LI D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes:systematic review and network meta-analysis[J]. BMJ, 2024, 384:e076410.
[34] ZHENG M, ZHAO J, WANG Y, et al. Exploring new therapeutic drugs for osteoarthritis and osteoporosis:glucagon-like peptide-1 receptor agonists:a review[J]. Medicine:Baltimore, 2025, 104(29):e43239.
[35] ZHA K X, AN Z M, GE S H, et al. FSH may mediate the association between HbA1c and bone turnover markers in postmenopausal women with type 2 diabetes[J]. J Bone Miner Metab, 2022, 40(3):468-477.
[36] JENSTERLE M, JANEZ A, FLIERS E, et al. The role of glucagon-like peptide-1 in reproduction:from physiology to therapeutic perspective[J]. Hum Reprod Update, 2019, 25(4):504-517.